Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation

Tzakis, Andreas G.; Kato, Tomoaki; Nishida, Seigo; Levi, David; Madariaga, Juan; Nery, Jose; Mittal, Naveen K; Regev, Arie; Cantwell, Patricia; Gyamfi, Anthony; Weppler, D.; Miller, Joshua; Tryphonopoulos, Panagiotis; Ruiz, Phillip

doi:10.1097/01.tp.0000065192.53065.50

Cited by 82 publications

(48 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alemtuzumab has since been used by ourselves and others in liver and intestinal transplantation with good shortterm results (16,17). More recently alemtuzumab has been used increasingly in the United State as an induction agent for kidney, pancreas, lung and liver transplantation, again with promising short-term results (18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation―Efficacy and Safety at Five Years

Watson

Bradley

Friend

et al. 2005

American Journal of Transplantation

216

112

View full text Add to dashboard Cite

Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation.Thirty-three renal transplant recipients received 20mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events.While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation―Efficacy and Safety at Five Years

Watson

Bradley

Friend

et al. 2005

American Journal of Transplantation

216

112

View full text Add to dashboard Cite

show abstract

“…For 20 patients (15 adults and 5 children), an induction protocol with Alemtuzumab (Campath-1H, ILEX Oncology, Inc., San Antonio, TX, USA) was used [34,35]. The remaining 27 patients received the same immunosuppression protocol as those in the first period.…”

Section: Methodsmentioning

confidence: 99%

Zoom endoscopic monitoring of small bowel allograft rejection

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Primary induction therapy with either rabbit antithymocyte globulin (rATG) (Thymoglobulin, Genzyme Corp., Cambridge, MA) or alemtuzumab (Campath-1H, Genzyme Corp., Cambridge, MA) is increasingly common [21][22][23][24]. Rejection is treated with optimization of tacrolimus levels, supplemental corticosteroids, and monoclonal or polyclonal antibody if necessary.…”

Section: Immunosuppressionmentioning

confidence: 99%

Current perspectives on pediatric intestinal transplantation

Mazariegos

Squires²,

Sindhi³

2009

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Irreversible intestinal failure in children is predominantly caused by surgical conditions such as volvulus, necrotizing enterocolitis, and gastroschisis. Functional intestinal failure from motility disorders such as intestinal pseudo-obstruction or enterocyte dysfunction with microvillus inclusion disease also may require intestine replacement. Approved indications for intestinal transplantation include liver dysfunction, loss of major venous access, frequent central line-related sepsis, and recurrent episodes of severe dehydration despite intravenous fluid management. Surgical options include transplantation of the isolated intestine, combined liver-intestine transplantation, or multivisceral transplantation of the stomach, duodenum, pancreas, and small bowel (with or without the liver). Immunosuppression for intestinal transplantation is based on tacrolimus therapy, often with induction immunosuppression using antilymphocyte antibodies (eg, antithymocyte antibody and alemtuzumab). Experience at centers of excellence demonstrates 1- and 5-year patient survival rates of 95% and 77%, respectively, with ongoing investigations focusing on lowering long-term causes of graft loss such as chronic rejection.

show abstract

Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation

Cited by 82 publications

References 9 publications

Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation―Efficacy and Safety at Five Years

Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation―Efficacy and Safety at Five Years

Zoom endoscopic monitoring of small bowel allograft rejection

Current perspectives on pediatric intestinal transplantation

Contact Info

Product

Resources

About